FOXO Technologies amends preferred stock terms and increases authorized shares via majority stockholder consent

FOXO TECHNOLOGIES INC.

Filed amendments to Series B and C Preferred Stock, revising conversion price to higher of $0.0001 or 90% of 5-day VWAP and removing mandatory conversion.
Majority stockholder Rennova Health (controlled by CEO) holding ~98.6% voting rights approved increase of Common Stock from 2.5B to 10B shares and Preferred from 10M to 20M shares.
Re-elected directors Seamus Lagan, Trevor Langley, Francis Colt deWolf III, Bret Barnes, and Mark White to board.
Ratified appointment of Kreit & Chiu CPA LLP as independent auditor for fiscal year 2025.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.